

COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS

(Currently amended claims showing deletions by ~~strikethrough~~ and additions by underlining; double brackets [[]] are also used to point out hard to read or difficult to notice amendments)

1. (Currently amended) A method of ~~combating~~ inhibiting the proliferation of breast cancer cells in a patient in need of such ~~combating~~ inhibition, ~~wherein the cancer is caused by the deregulation of expression of proteins having a role in regulating tumor cells and wherein said breast cancer cells~~ [[is]] are characterized by ~~an over-~~ increased expression of peripheral-type benzodiazepine receptor protein, which comprises:

determining whether said breast cancer cells exhibit elevated expression of peripheral-type benzodiazepine receptor protein, wherein said elevated expression is an at least 3-fold increase in the level of expression of peripheral-type benzodiazepine receptor protein as compared to normal cells; and

administering an effective amount of a Ginkgo biloba extract containing Ginkgolide B or of isolated Ginkgolide B to said patient.

2-4. (Canceled)

5. (Currently amended) A method ~~of combating cancer in a patient~~ according to claim [[2]] 1, wherein said proliferation of breast cancer cells is caused by the over-expression of oncogenes, and wherein the administering results in decreasing the expression of said oncogenes and combats the proliferation of said breast cancer cells.

6. (Original) A method according to claim 5, wherein said oncogenes are one or more of APC, PE-1, RhoA and c-Jun.

7. (Currently amended) A method ~~of combating cancer in a patient~~ according to claim 1, ~~wherein said deregulation of the expression of proteins results in cancer cells expressing an abnormal level of peripheral-type benzodiazepine receptor relative to normal cancer cells, and wherein said administering results in decreasing the expression of peripheral-type benzodiazepine receptor in said breast cancer cells.~~

Applicant : DRIEU, Katy
Serial No. : 10/018,448
Filed : March 30, 2002
Page : 3

8. (Currently amended) A method according to claim 7, wherein said breast cancer cells are human breast cancer cells.

9-15. (Canceled)

16. (Currently amended) A method according to claim 7, wherein the decreasing of the expression of peripheral-type benzodiazepine receptor is the result of decreasing the expression of peripheral-type benzodiazepine receptor mRNA in said breast cancer cells.

17. (Currently amended) A method ~~of combating cancer in a patient~~ according to claim 1, wherein said ~~deregulation of expression~~ administering results in increasing the expression of a c-Myc protooncogene.

18. (Currently amended) A method ~~of combating cancer in a patient~~ according to claim 1, wherein said ~~deregulation of expression~~ administering results in decreasing the expression of cell cycle regulators prothymosin- α , CDK2, p55CDC, myeloblastin and p120 proliferating-cell nuclear antigen.

19. (Currently amended) A method ~~of combating cancer in a patient~~ according to claim 1, wherein said ~~deregulation of expression~~ administering results in decreasing the expression of intracellular signal transduction modulators NET1 and ERK2.

20. (Currently amended) A method ~~of combating cancer in a patient~~ according to claim 1, wherein said ~~deregulation of expression~~ administering results in decreasing the expression of apoptosis-related products Adenosine A2A Receptor, Flt3 ligand, Grb2, Clusterin, RXR- β , Glutathione S-transferase P, N-Myc, TRADD, SGP-2 and NIP-1.

21. (Currently amended) A method ~~of combating cancer in a patient~~ according to claim 1, wherein said ~~deregulation of expression~~ administering results in decreasing the expression of transcription factors Id-2, ATF-4, ETR101 and ETR-103.

22. (Currently amended) A method ~~of combating cancer in a patient~~ according to claim 1, wherein said ~~deregulation of expression~~ administering results in decreasing the expression of growth factors macrophage colony-stimulating factor-1, heparin-binding EGF-like growth factor, hepatocyte growth factor-like protein and inhibin α .

Applicant : DRIEU, Katy
Serial No. : 10/018,448
Filed : March 30, 2002
Page : 4

23. (Currently amended) A method ~~of combating cancer in a patient~~ according to claim 1, wherein said ~~deregulation of expression~~ administering results in decreasing the expression of cell adhesion molecules CD19 B-lymphocyte antigen, L1CAM, β -catenin, integrin subunits α 3, α 4, α 6, β 5, and α M.

24. (Currently amended) A method ~~of combating cancer in a patient~~ according to claim 1, wherein said ~~deregulation of expression~~ administering results in decreasing the expression of genes APC, PE-1, RhoA, c-Jun, prothymosin- α , CDK2, p55CDC, myeloblastin, p120 proliferating-cell nuclear antigen, NET1, ERK2, Adenosine A2A Receptor, Flt3 ligand, Grb2, Clusterin, RXR- β , Glutathione S-transferase P, N-Myc, TRADD, SGP-2, NIP-1, Id-2, ATF-4, ETR-101, ETR-103, macrophage colony-stimulating factor-1, heparin-binding EGF-like growth factor, hepatocyte growth factor-like protein, inhibin α , CD19 B-lymphocyte antigen, L1CAM, β -catenin, and integrin subunits α 3, α 4, α 6, β 5, and α M.

25-26. (Canceled)

27. (New) A method according to claim 1, wherein said Ginkgo biloba extract containing Ginkgolide B administered in an effective amount is Ginkgo biloba extract EGB 761.

28. (New) A method according to claim 1, wherein Ginkgolide B is administered in an effective amount.